Disrupt Pain Without Opioids. While other treatments dull pain, Latigo’s solutions target the source of pain before it reaches the central nervous system. The result is healing without dependence, and relief that can help restore quality of life.
Location: United States, California, Thousand Oaks
Total raised: $135M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.02.2024 | Series A | $135M | - |
Mentions in press and media 4
| Date | Title | Description |
| 20.02.2024 | Latigo Biotherapeutics: A Pain-Relief Powerhouse Emerges | Latigo Biotherapeutics, a clinical-stage biotechnology company from Thousand Oaks, CA, has secured a whopping $135M in Series A funding. Led by Westlake Village BioPartners, this funding will propel the development of non-opioid pain medici... |
| 14.02.2024 | Latigo Biotherapeutics Finds $135M | Thousand Oaks-based Latigo Biotherapeutics, a biotherapeutics company developing non-opioid pain medications, says it has raised $135M in a Series A funding round. The funding was led by Westlake Village BioPartners, which originally incuba... |
| 14.02.2024 | Latigo Biotherapeutics Raises $135M in Series A Financing | Desmond Padhi, PharmD, Latigo Biotherapeutics interim CEO Latigo Biotherapeutics, a Thousand Oaks, CA-based clinical-stage biotechnology company developing non-opioid pain medicines that target pain at its source, raised $135M in Series A f... |
| - | Latigo Biotherapeutics | “Disrupt Pain Without Opioids. While other treatments dull pain, Latigo’s solutions target the source of pain before it reaches the central nervous system. The result is healing without dependence, and relief that can help restore quality o... |